Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q01970
UPID:
PLCB3_HUMAN
Alternative names:
Phosphoinositide phospholipase C-beta-3; Phospholipase C-beta-3
Alternative UPACC:
Q01970; A5PKZ6; G5E960; Q8N1A4
Background:
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3, also known as Phosphoinositide phospholipase C-beta-3 and Phospholipase C-beta-3, plays a crucial role in cell signaling by generating diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). These second messenger molecules are pivotal in transmitting signals from various growth factors and hormones.
Therapeutic significance:
This protein's mutation is linked to Spondylometaphyseal dysplasia with corneal dystrophy, a disorder affecting growth, limb development, and intellectual ability. Understanding the role of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 could open doors to potential therapeutic strategies for this and related conditions.